BioTuesdays

Category - Developments

Adamis Pharma

FDA accepts Adamis NDA resubmission

The FDA has accepted for review Adamis Pharmaceuticals’ (NASDAQ:ADMP) NDA for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis. Filed last Dec. 15, the resubmission...

Vital Therapies

Vital Therapies updates Phase 3 trial

Vital Therapies (NASDAQ:VTL) updated its Phase 3 trial, VTL-308, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis. A total of 38 subjects have been enrolled at sites in the U.S. and...

IntelGenx

IntelGenx, Chemo Group sign CNS accord

IntelGenx Technologies (OTCQX:IGXT; TSX-V:IGX) has signed a definitive agreement with Chemo Group for the co-development and commercialization of a generic tablet in the area of CNS on a worldwide basis. According to...

Titan Pharmaceuticals

Braeburn files for $150-million IPO

Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA...

IntelGenx

IntelGenx in development pact with Endo

IntelGenx (OTCQX:IGXT; TSX-V:IGX) entered into a co-development and commercialization agreement with Endo Ventures for a new product utilizing IntelGenx’ proprietary VersaFilm for the USA market. Under the accord...

Dipexium Pharmaceuticals

Dipexium, PLx Pharma agree to merge

Dipexium Pharmaceuticals (NASDAQ:DPRX) and closely held PLx Pharma have agreed to merge in an all-stock transaction.  Following closing, Dipexium will be renamed PLx Pharma and will operate under the leadership of...